Yeah exactly DrugDoctor...because if not then they will more than likely be joining the list of the other 'Top MSOs' that have revised guidance. Except they tend to use 'Annualized Run Rate'. Either way, a decrease in the approximation wont help the stock price.
Q4 2022 Projected Revenue Annualized Run Rate of Approximately $220 Million - $260 Million Q4 2022 Projected Adjusted EBITDA Annualized Run Rate of Approximately $70 Million - $82 Million